Natriuretic peptides and collagen biomarkers in patients with medical treatment for hypertension

Acta Cardiologica

Volumn 66, Issue 1, 2011, Pages 21-27

  Uusimaa, Paavo ^a,b   Peuhkurinen, Sini ^a   Ylitalo, Antti ^b,c   Vuolteenaho, Olli ^a   Risteli, Juha ^a   Peuhkurinen, Keijo ^b,d  

^a UNIVERSITY OF OULU   (Finland)

^b OULU DEACONESS INSTITUTE   (Finland)

^c SATAKUNTA CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Amlodipine; Atenolol; Collagen; Hypertension; Natriuretic peptides

Indexed keywords

AMLODIPINE; ATENOLOL; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; PROCOLLAGEN C PROTEINASE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE;

ADULT; ARTICLE; BLOOD PRESSURE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL;

AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ATENOLOL; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; COLLAGEN; HUMANS; HYPERTENSION; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROCOLLAGEN; VENTRICULAR REMODELING;

EID: 79952050155     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.66.1.2064963     Document Type: Article

References (21)

1. Kjeldsen SE, Dahlöf B, Devereux RB, Julius S, Aurup P, Edelman J, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn S, Wedell H for the LIFE Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. JAMA 2002; 288: 1491-8
2. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-6
3. Kohno M, Horio T, Yokokawa K, Yasunari K, Ikeda M, Minami M, Kurihara N, Takeda T. Brain natriuretic peptide as a marker for hypertensive left ventricular hypertrophy: Changes during 1-year antihypertensive therapy with angiotensin-converting enzyme inhibitor. Am J Med 1995; 98: 257-65
4. Talwar S, Siebenhofer A, Williams B, Ng L. Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP. Heart 2000; 83: 278-82
5. Rubattu S, Sciarretta S, Ciavarella GM, Venturelli V, De Paolis P, Tocci G, De Biase L, Ferrucci A, Volpe M. Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass. J Hypertension 2007; 25: 833-9
6. Mottram PM, Leano R, Marwick TH. Usefulness of B-type natriuretic peptide in hypertensive patients with exertional dyspnea and normal left ventricular ejection fraction and correlation with new echocardiographic indexes of systolic and diastolic function. Am J Cardiol 2003; 92: 1434-8
7. Uusimaa P, Tokola H, Ylitalo A, Vuolteenaho O, Ruskoaho H, Risteli J, Ylitalo A, Peuhkurinen K on behalf of the Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Plasma B-type natriuretic peptide reflects left ventricular hypertrophy and diastolic function in hypertension. Int J Cardiol 2004; 97: 251-6
8. Díez J, Laviades C, Mayor G, Gil MJ, Monreal I. Increased serum concentrations of procollagen peptides in essential hypertension. Relation to cardiac alterations. Circulation 1995; 91: 1450-6
9. Uusimaa P, Risteli J, Niemelä M, Lumme J, Ikäheimo M, Jounela A, Peuhkurinen K. Collagen scar formation after acute myocardial infarction. Relationships to infarct size, left ventricular function and coronary artery patency. Circulation 1997; 96: 2565-72
10. López B, Querejeta R, Varo N, Laviades C, Querjeta R, Díetz J. Usefulness of serum carboxy-terminal propeptide of procollagen type I in assessment of the cardioreparative ability of antihypertensive treatment in hypertensive patients. Circulation 2001; 104: 286-91
11. Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Östergren J, Pocock S for the ASCOT investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-13
12. Uusimaa P, Tokola H, Ruskoaho H, Vuolteenaho O, Risteli J, Ylitalo A, Peuhkurinen K on behalf of the ASCOT investigators. Vasoactive peptides and procollagen propeptides in patients with hypertension in relation to cardiac hypertrophy and diastolic heart failure: design of the study and patient characteristics. J Hum Hypertension 2001; 15(suppl 1): S19-S22.
13. Müller-Brunotte R, Kahan T, Malmqvist K, Ring M, Edner M. Tissue velocity echocardiography shows early improvement in diastolic function with erbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA). Am J Hypertens 2006; 19: 927-36
14. Solomon SC, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D, Lacourcière Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JMO, Thomas JD, Zile MR, Aurigemma GP for the Valsartan in Diastolic Dysfunction (VALIDD) Investigators. Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet 2007; 369: 2079-87
15. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt BR. Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy. J Hypertension 2005; 23: 1083-90
16. Ohbayashi Y, Tsutamoto T, Sakaguchi T, Tanaka T, Kanamori T, Yokohama H, Sichiri G, Hukai D, Okabayashi T, Ozawa T, Ishii C, Tsutsui T, Ohno K, Ohnishi M, Wada A. Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine. J Cardiovasc Pharmacol 2003; 42(Suppl 1): S71-S74.
17. Olsen MH, Wachtell K, Tuxen C, Fossum E, Bang LE, Hall C, Ibsen H, Rokkedal J, Devereux RB, Hildebrandt P. N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertension 2004; 22: 1597-1604
18. Olsen MH, Christensen MK, Wachtell K, Tuxen C, Fossum E, Bang LE, Wiinberg N, Devereux RB, Kjeldsen SE, Hilderandt P, Dige-Petersen H, Rokkedal J, Ibsen H. Markers of collagen synthesis is related to blood pressure and vascular hypertrophy: a LIFE substudy. J Hum Hypertension 2005; 19: 301-7
19. Ciulla MM, Paliotti R, Esposito A, Diez J, López P, Dahlöf B, Nicholls G, Smith RD, Gilles L, Magrini F, Zanchetti A. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis. Results of a randomized trial. Circulation 2004; 110: 552-7
20. Nishikawa N, Masayama T, Yamamoto K, Skata Y, Mano T, Miwa T, Sugawara M, Hori M. Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats. J Am Coll Cardiol 2001; 38: 1539-45
21. Rajzer M, Klocek M, Kaweck-Jaszcz K. Effect of amlodipine, quinapril, and losartan on pulse wave velocity and plasma collagen markers in patients with mild-to-moderate arterial hypertension. Am J Hypertension 2003; 16: 439-44